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Abstract
Background: Disease management programmes are heterogeneous in nature and often lack a theoretical basis.
An evaluation model has been developed in which theoretically driven inquiries link disease management
interventions to outcomes. The aim of this study is to methodically evaluate the impact of a disease management
programme for patients with chronic obstructive pulmonary disease (COPD) on process, intermediate and final
outcomes of care in a general practice setting.
Methods: A quasi-experimental research was performed with 12-months follow-up of 189 COPD patients in
primary care in the Netherlands. The programme included patient education, protocolised assessment and
treatment of COPD, structural follow-up and coordination by practice nurses at 3, 6 and 12 months. Data on
intermediate outcomes (knowledge, psychosocial mediators, self-efficacy and behaviour) and final outcomes
(dyspnoea, quality of life, measured by the CRQ and CCQ, and patient experiences) were obtained from
questionnaires and electronic registries.
Results: Implementation of the programme was associated with significant improvements in dyspnoea (p < 0.001)
and patient experiences (p < 0.001). No significant improvement was found in mean quality of life scores.
Improvements were found in several intermediate outcomes, including investment beliefs (p < 0.05), disease-
specific knowledge (p < 0.01; p < 0.001) and medication compliance (p < 0.01). Overall, process improvement was
established. The model showed associations between significantly improved intermediate outcomes and
improvements in quality of life and dyspnoea.
Conclusions: The application of a theory-driven model enhances the design and evaluation of disease
management programmes aimed at improving health outcomes. This study supports the notion that a theoretical
approach strengthens the evaluation designs of complex interventions. Moreover, it provides prudent evidence
that the implementation of COPD disease management programmes can positively influence outcomes of care.
Background
Due to aging of the population, numbers of persons suf-
fering from chronic conditions are growing at astonish-
ing rates. Chronic illnesses will be the primary cause of
death and disability in the world by 2020 [1]. Among
the most common chronic diseases is chronic obstruc-
tive pulmonary disease (COPD), which represents an
enormous burden on individuals, families and societies,
by its impact on quality of life, health resource utilisa-
tion, and mortality [2-4]. The causes and maintaining
factors of chronic conditions are complex; therefore a
multifaceted, multidisciplinary and multi-institutional
response is needed [1]. Models of care coordination,
such as disease management, capture the complexity of
providing health care for chronic conditions in a coordi-
nated manner. They also underscore the importance of
using multifaceted approaches as opposed to “magic
bullet” or single interventions [5]. Multifaceted pro-
grammes offer different combinations of interventions
directed at patients, professionals and/or the organisa-
tion of care [6]. Although these programmes vary widely
in structure and style, the primary goals - to improve
disease outcomes while containing overall healthcare
costs - tend to be consistent.
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Yet it is the very heterogeneity of the programmes
that makes it hard to evaluate them and compare them
on results. An evaluation model has therefore been
developed to structurally evaluate disease management
programmes, in which theoretically driven inquiries link
disease management interventions to outcomes achieve-
ment [6]. In this paper this model was applied to a
COPD disease management programme implemented in
the ‘Gelderse Vallei’ region in central Netherlands.
Seven general practices to that aim cooperated with the
regional hospital and home care organisation. The pro-
gramme includes three main features: patient education,
protocolised assessment and treatment of COPD, and
coordination of care. This study reports on the effects of
the implementation of this programme on process,
intermediate and final outcome indicators as derived
from the evaluation model. It is hypothesised that the
implementation of multiple disease management inter-
ventions will influence intermediate and eventually final
outcomes of care.
Theoretical framework
Determining the effectiveness of complex interventions
requires understanding of the components of an inter-
vention and their interrelationships ("black box”) [6,7].
The theoretically derived evaluation framework, which is
based on social learning theories, links the disease man-
agement components with the underlying mechanisms
by which they influence outcomes, and proposes direct
and indirect relationships among them. The framework
has been described in detail elsewhere [6] and includes
three key components: patient-related and professional-
directed interventions, supported by the organisational
design. Theoretical approaches on organisational and
behavioural change are integrated, supporting the
premise that combing these interventions strengthens
the effects of disease management. The various compo-
nents and indicators defined in this study are shown in
Figure 1. A distinction was made between process indi-
cators (what is done), intermediate indicators (proce-
dural end point, i.e. behaviour change) and final
outcome indicators (end results of care, i.e. change in
patient health status) [8]. In this paper, the model will
be put to the test for the very first time.
To test the model we will first examine the actual
implementation of the COPD disease management pro-
gramme in the ‘Gelderse Vallei’ region through process
evaluation. Changes in intermediate and final outcomes
of care are expected to result from programme imple-
mentation. Next, because both patient-related and pro-
fessional-directed interventions aim to alter behaviour
through mechanisms such as gaining knowledge, skills
Figure 1 Disease management evaluation model for the ‘Gelderse Vallei’ region.
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and/or self-efficacy we will also evaluate the extent to
which evidence-based care is provided. And, finally, we
will analyse if the presumed patient behavioural change -
due to improving knowledge, psychosocial beliefs and
self-efficacy - contributes to the attainment of expected
outcomes.
Methods
Study design
The study was designed as an one-group pre-post test
study [9]. This design was chosen to test the theoretical
basis and components of this complex intervention and
is also an opportunity to determine the consistency with
which the intervention is delivered [10]. Composition of
a control group was not feasible, due to involvement of
other regional practices in the implementation of inno-
vations which would bias the study of usual care
practices.
Participants and setting
The programme was carried out in seven general prac-
tices (12 general practitioners (GPs)) in the ‘Gelderse
Vallei’ region in central Netherlands. The practices were
solo (43%), duo (28%) and small group practices (28%)
(on average 2700 patients per fulltime unit GP); most
GPs were male (67%). Practice characteristics were
representative of other practices in this region and also
of Dutch practices in general (Additional file 1) [11,12].
These practices cooperated with the regional hospital.
The practices were supported by practice nurses of a
regional home care organisation. Patients were recruited
between April 2006 and August 2006. All known COPD
patients, as well as individuals who satisfied predefined
criteria (aged ≥ 40, previous use of COPD or asthma
medication and International Classification of Primary
Care (ICPC) codes COPD (R95) or asthma (R96)), were
invited for diagnostic assessment. The practice nurses
identified eligible patients supported by the GP and an
electronic protocol. Patients with a confirmed diagnosis
of COPD, according to Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria which
include confirmation by spirometry [13], were invited to
participate, and informed consent was obtained. Patients
with serious co-morbidity, for instance congestive heart
failure, were not eligible for inclusion.
Disease management interventions
The COPD disease management programme consisted
of three facets (Additional file 2): One, a patient-related
intervention designed to increase patients’ understanding
of the condition and to teach them specific prevention
or treatment strategies on smoking behaviour, medica-
tion usage, nutrition and physical activity. In practice
this intervention was offered during each contact for at
least fifteen minutes (patient-education). An information
booklet was provided as well. Secondly, a professional-
directed intervention designed to educate professionals
on the guidelines and programme (protocolised assess-
ment and treatment of COPD). Over twelve months,
GPs attended three courses on standardised COPD
management and spirometry training. Before the intro-
duction of the programme the practice nurses received
six days of training in standardised COPD management
and the provision of medical and non-medical treat-
ment. The training was designed to reinforce knowledge
on diagnosing COPD, assessing COPD severity, patient
self-management, smoking cessation, follow-up, and
planning possible action against exacerbations. Both GPs
and practice nurses were trained in the application of
spirometry. The implementation of the guidelines was
supported by an electronic diagnostic and treatment
protocol. Third, these interventions were supported by
organisational interventions consisting of structural fol-
low-up, case management and multidisciplinary colla-
boration. A multidisciplinary team cooperated in a
system for coordinating diagnostic procedures, treat-
ment, and ongoing patient management (coordination
of care). The tasks and responsibilities of the members
(GP, practice nurse and a lung specialist) were described
in a guideline-based protocol. The practice nurses per-
formed diagnostic tests such as lung function measure-
ments, assessed patients’ conditions, provided disease-
related education and advice, coordinated care, and
organised follow-up meetings at 3, 6 and 12 months.
They acted in conjunction with the GP who consulted
the specialist when needed. Generally, telespirometry
was used to confirm the diagnosis; the test results in the
general practice were dispatched through a simple tele-
phone call to the lung specialist who was able to make a
functional diagnosis.
Data collection
Data on patient intermediate outcomes as well as quality
of life and satisfaction were collected by means of postal
questionnaires. The following patient characteristics
were also gathered: age, gender, education and marital
status. Professional behaviour and clinical outcome data
were obtained from an electronic registry, which was
part of the software protocol for treatment and monitor-
ing of COPD patients in participating practices. Process
data were gathered by means of a survey among
professionals.
Process
Actual exposure to the disease management programme
was evaluated by the Assessing Chronic Illness Care
(ACIC) survey [14]. In this study, only the process ele-
ments reflecting the programme’s interventions were
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included: self-management support (patient-related
intervention), decision support (professional-directed
intervention), as well as delivery system design and clini-
cal information system (both organisational interven-
tions). Professionals rated the 4 to 6 items per element
on a 1 to 11 scale, with higher scores indicating greater
implementation. A mean score for each element was
obtained. These data were validated with the care regis-
tries’ process data
Intermediate outcomes
Compliance and disease-specific knowledge were mea-
sured using a validated Dutch-language instrument [15].
Objective knowledge was measured by means of 22 true
or false questions about COPD and expressed as the
proportion of correct answers, transformed into a 0-10
scale. Subjective knowledge was assessed by means of
six questions on a five-point scale indicating the estima-
tion that patients make of their amount of knowledge
on COPD. Self-reported medication compliance and
physical activity practice were both measured by
numeric rating (0-10) in combination with questions on
a five-point scale that were expressed as one overall
score. Next to that, self-reported smoking behaviour was
measured on a dichotomous scale. Psycho-social media-
tors and self-efficacy were assessed using three dimen-
sions of the Self-Management Ability Scale (SMAS):
investment (the ability to invest in longer-term benefits)
and initiative beliefs (the ability to be self-motivating
regarding the realisation of the dimensions of well-
being), as well as self-efficacy [16,17]. The subscales
each consist of five items rated on a six-point scale. A
higher score indicated better ability.
Professional behaviour was measured from the degree
to which GPs applied evidence-based care after the
intervention. Professional adherence to protocolised
assessment and treatment of COPD was measured by
four main guideline aspects: GOLD classification with
each COPD diagnosis, application of spirometry, pre-
scription of airway medication and inspection of
patients’ medication usage and technique. The applica-
tion of patient education was evaluated from the pro-
portions of patients reporting they had received clear
information and information booklets. Continuity of
care was assessed from the proportions of patients regu-
larly followed. The indicators are expressed as percen-
tages of patients that received a specific intervention.
Final outcomes measures
A validated Dutch version of the self-reported Chronic
Respiratory Questionnaire (CRQ-SR) was used to mea-
sure quality of life [18,19]. The CRQ-SR is made up of
20 questions and measures four dimensions relating to
dyspnoea (5), emotional function (7), fatigue (4), and
mastery (4). For every question there are seven response
categories that score from 1 to 7; higher scores indicated
better quality of life. A change of 0.5 in each dimension
has been calculated as being the minimum clinically
important difference (MCID) [19].
Additionally, the Clinical COPD Questionnaire (CCQ)
was used, a self-administered multidimensional symp-
tom control questionnaire that includes 10 questions in
three domains: symptoms (4), functional (4) and mental
state (2) [20]. The total CCQ score, and the score on
each of the three domains, varies between 0 (very good
health status) to 6 (extremely poor health status). An
average change in score of 0.4 for the total score has
been shown to be the MCID [20].
The EQ-5D visual analogue scale (VAS), a “thermo-
meter” for eliciting a self-rating of health status, was
used. Patients mark their perceived health status on a
line with anchors 0 (worst imaginable health state) and
100 (best imaginable health state) [21].
The Medical Research Council (MRC) scale is a com-
monly used, validated, ordinal scale on which patients
rate the type and magnitude of their dyspnoea according
to five grades of increasing severity: 0 indicating ‘breath-
lessness with strenuous exercise’ to 5 representing
‘breathlessness keeping patients from leaving the house’
[22]. Dyspnoea was also measured by the modified Borg
scale, a 0 to 10 rated scale to measure and evaluate
patients’ dyspnoea [23].
Lung function was assessed by measuring the forced
expiratory volume in one second (FEV1) with the use of
spirometry and expressed as FEV1percentage predicted,
according to established criteria [13]. FEV1 was mea-
sured from a series of at least three forced expiratory
curves that had an acceptable start of test and were free
from artefact.
Patients’ experiences on quality of care were measured
using a self-administered questionnaire, the QUOTE
(QUality Of care Through the patients’ Eyes) COPD
[24]. In this study, only indicators reflecting aspects of
quality of care specifically targeted by the programme’s
interventions were included, namely coordination and
accessibility of care, education on medication use and
non-medical self-care.
Statistical analyses
Comparisons for all study variables were made between
baseline and 12 months post-intervention using paired-
sampled t-tests and Wilcoxon signed rank tests (two-
sided; a = 0.05) where appropriate. To determine if the
theoretical model propositions are consistent with the
data, regression analyses were applied in two steps.
Intermediate indicators (independent variables) with sig-
nificant changes in means entered the regression model
with changes in outcomes as subsequent dependent
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variables. In accordance with the theoretical model first
investment beliefs, subjective and objective knowledge
entered the equation and then medication compliance.
Even though outcome measures did not change signifi-
cantly, within group variation in outcomes made it feasi-
ble to perform these regression analyses. Scores are
arranged so that positive correlations indicate a positive
relation. All analyses were performed at patient level.
Data processing and analysis were performed using
SPSS 15 for Windows. A prior significance level of 0.05
was used for all statistical tests.
Results
Patient inclusion, assignment and follow-up
Two hundred fifty-nine patients were found eligible to
participate in the disease management programme, of
whom 189 (73%) consented to participate in the study.
Participants did not significantly differ at baseline with
regard to sex, age and stage of COPD (p < 0.05) from
the patients that did not participate in the study.
Table 1 shows baseline characteristics of all participants
and those for whom data collection was complete (150/
189; 79%). Most patients had mild or moderate forms of
COPD, which make up the majority of the COPD popu-
lation [25]. A comparison of drop-outs with patients
that completed the study revealed no clinical differences
on any baseline characteristics and quality of life mea-
sures. The most common reason for dropping out of
the study was unwillingness to complete questionnaires;
questionnaires were resend when they were not
returned.
Process evaluation
Table 2 summarises the extent to which the caregivers
felt that the disease management programme was actu-
ally implemented. Although all scores increased, those
for decision support and self-management support chan-
ged the least and were not significant. Scores on organi-
sational interventions, delivery system design and
clinical information system, had improved significantly
after 12 months (p = 0.012 and p ≤ 0.001, respectively).
Intermediate outcomes
Objective and subjective measurement of knowledge
improved significantly (p = 0.002 and p ≤ 0.001,
respectively). Variables related to self-efficacy and psy-
chosocial beliefs remained the same or improved, the
difference in investment beliefs being statistically sig-
nificant (p = 0.049). Compliance with the medication
regimen has improved after 12-months follow up (p =
0.003), unlike smoking status or physical activity prac-
tice (Table 3).
Table 1 Baseline characteristics
Baseline characteristics Total population
(n = 189)
Completed data
(n = 150)
Mean ± SD Mean ± SD
Age 66 (± 11) 66 (± 11)
Lung function (FEV1) 75.7 (± 18.6) 75.4 (± 18.6)
Tiffeneau 63.6 (± 11.4) 63.9 (± 11.1)
Dyspnoea 1.68 (± 1.09) 1.65 (± 1.07)
Body Mass Index 27.0 (± 4.2) 27.1 (± 4.3)
% (n) % (n)
Sex
Male 65 (122) 67 (100)
Female 35 (67) 33 (50)
Marital status
Married or equivalent 80 (149) 81 (120)
Widowed 10 (19) 11 (16)
Divorced 2 (3) 2 (3)
Never married 8 (15) 6 (9)
Educational level greater than high school diploma 24 (46) 26 (39)
Smoking status
Non or Ex-smoker 74 (139) 77 (115)
Current smoker 26 (50) 23 (35)
COPD severity
GOLD 1 (Mild) 47 (90) 46 (69)
GOLD 2 (Moderate) 40 (75) 43 (64)
GOLD 3 (Severe) 13 (24) 11 (17)
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With regard to professional behaviour, all patients
were diagnosed with spirometry and were classified
according to the GOLD criteria. Airway medication was
mostly prescribed in line with guideline recommenda-
tions (92%). Correct use of medication by patients was
checked for 92% of the patients. Seventy-eight percent
of the patients reported to have received clear informa-
tion (78%), however only 56% had received an informa-
tion booklet. Ninety-two percent of patients regularly
attended follow-up meetings.
Final outcomes of care
Table 4 summarises the findings for all clinical out-
comes, quality of life variables and patient experiences,
comparing the baseline measurement with the
12-month measurement and determining statistical sig-
nificance of the difference. Dyspnoea had improved
significantly on both MRC (p ≤ 0.001) and Borg scale
(p ≤ 0.001). A significant decline with regard to lung
function was found. Clinically and statistically signifi-
cant improvements were not found on quality of life
scores (according to the CRQ, CCQ and VAS). Overall,
patient experiences with practice nurses, as measured
by QUOTE, had improved (p < 0.001). More specifi-
cally, improvements were found on the subscales
accessibility, education on medication use and on non-
medical self care. Improvement on patient experiences
with GPs was only found for the subscale on accessi-
bility (p = 0.016).
Testing the Evaluation Model’s propositions
Table 5 shows the results of the hierarchical regression
analyses that explored the associations between changes
in intermediate outcomes and changes in outcomes of
care. Changes in investment beliefs and/or subjective
knowledge were found to be significant predictors of
changes in CRQ, CCQ and health status scores. No
direct or mediating effect was found of medication com-
pliance on outcomes of care. Additional analyses showed
that including all intermediate variables did not influ-
ence our results.
Discussion
The objective of this study was to evaluate the effective-
ness of a disease management programme for COPD
patients according to the evaluation model and to explore
associations between the model elements. Implementa-
tion of the programme was associated with significant
improvements in dyspnoea and patient experiences with
the practice nurses, whereas quality of life measures
remained stable. It would seem, therefore, that symptoms
may improve despite worsening of lung function para-
meters [26]. COPD is a progressive disease and lung
function can be expected to worsen over time [27].
Table 2 Process improvement
Dimension† Baseline
(Mean ± SD)
12 months
(Mean ± SD)
Change
(95% CI)
p-value
Patient-related (Self-management support) 5.97 (± 2.44) 6.93 (± 2.11) 0.95 (-0.46; 2.36) 0.163
Professional-directed (Decision support) 6.88 (± 1.40) 7.86 (± 1.63) 0.98 (-0.13; 2.09) 0.079
Organisational (Delivery system design) 6.67 (± 1.45) 7.97 (± 1.51) 1.30 (0.35; 2.24) 0.012*
Organisational (Clinical information system) 5.83 (± 1.17) 7.03 (± 1.23) 1.20 (0.68; 1.73) 0.000*
† Positive change means improvement
Table 3 Changes in intermediate outcomes
Indicator Baseline
(Mean ± SD)
12 months
(Mean ± SD)
Change
(95% CI)
p-value
Psycho-social mediators†
Initiative beliefs (scale 1-6) 4.04 (± 0.74) 4.10 (± 0.77) 0.06 (-0.06; 0.18) 0.335
Investment beliefs (scale 1-6) 4.13 (± 0.76) 4.24 (± 0.74) 0.10 (0.01; 0.20) 0.049
Self-efficacy†
Self-efficacy (scale 1-6) 4.24 (± 0.74) 4.23 (± 0.78) -0.01 (-0.11; 0.10) 0.865
Knowledge on COPD†
Subjective knowledge (scale 1-5) 2.84 (± 0.84) 3.22 (± 0.82) 0.38 (0.24; 0.51) 0.000
Objective knowledge (scale 1-10) 4.49 (± 2.10) 4.92 (± 2.03) 0.43 (0.16; 0.69) 0.002
Behaviour
Smoking status* (% smoking) 23% 22% 1% 0.180
Medication compliance† (scale 1-5) 4.41 (± 0.63) 4.58 (± 0.58) 0.17 (0.05; 0.28) 0.003
Physical activity† (scale 1-5) 2.80 (± 0.54) 2.85 (± 0.53) 0.05 (-0.02; 0.12) 0.167
* Negative change means improvement; † Positive change means improvement
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Improvements were also found in several intermedi-
ate outcomes, including investment beliefs, disease-
specific knowledge and medication compliance. The
model associations were examined, and investment
beliefs and subjective knowledge proved to be predic-
tors of quality of life and health status. This would
indicate that increasing patients’ ability to invest in
longer-term benefits positively relates to outcomes of
care. In contrast with our model, no direct or mediat-
ing effect was found of behaviour change. This may be
due to the absence of significant changes in physical
and smoking behaviour. However, direct relations
between knowledge gain and investment beliefs (inde-
pendent variables) and quality of life (dependent vari-
able) were found; suggesting the direct influence of
cognitive processes on quality of life.
The findings in our study are to some extent consis-
tent with results from other studies on the effectiveness
of COPD disease management: improved patient satis-
faction and process measures [28] and inconclusive
results on quality of life [29-32]. However, earlier studies
focussed on single components [29] rather than on pro-
grammes that did include all three components. This
study presents an example of a theory-based evaluation
of disease management. This in contrast with studies on
other complex interventions that are often defined prag-
matically and lack any clear theoretical basis [33]. Pro-
cess, intermediate as well as final outcome indicators
should be selected on theoretical grounds, as was done
in this study.
Several factors might have influenced the effect size of
the programme in this study. The multidimensional and
multidisciplinary nature of disease management in addi-
tion to the amount of time it takes to detect changes,
presents further challenges in developing an evidence
base within a time and financially limited research pro-
ject. The 12 months follow-up period may have been
too brief to observe all changes resulting from the inter-
vention, since major effects of disease management
interventions are expected to occur in the long term
[34]. Over time, changes found in intermediate out-
comes may be predictors of improvements, particularly
in quality of life. Moreover, the patients in this study
had less severe disease than those in some other studies,
potentially reducing possibilities to detect improvement
in our sample. And finally, even though all process
implementation measures improved, full implementation
of the programme was not always reached. For example,
evidence-based care provision by professionals was hin-
dered by distribution problems of the information book-
let to the practice nurses.
Furthermore, intensity of the patient-related interven-
tion, which is crucial for improving skills, ability to cope
with illness, and health status [13], may have been too
low. This could explain why changes in self-efficacy
were not observed. And even though physical activity is
an important predictor of outcomes in COPD care [35],
it did not change significantly as a result of the interven-
tion. Greater attention to physical activity and smoking
cessation is indicated, therefore. The inclusion of a
Table 4 Changes in outcomes of care
Outcome indicator Baseline
(Mean ± SD)
12 months
(Mean ± SD)
Change
(95% CI)
p-value
Quality of life
CRQ† (scale 1-7)
CRQ (dyspnoea) 5.68 (± 1.33) 5.70 (± 1.33) 0.02 (-0.13; 0.16) 0.823
CRQ (emotional function) 5.39 (± 1.05) 5.34 (± 1.10) -0.04 (-0.19; 0.10) 0.551
CRQ (fatigue) 4.79 (± 1.27) 4.85 (± 1.27) 0.53 (-0.10; 0.21) 0.515
CRQ (mastery) 5.63 (± 1.07) 5.64 (± 1.07) 0.01 (-0.17; 0.19) 0.895
CCQ (total)* (scale 0-6) 1.38 (± 0.84) 1.45 (± 0.92) 0.07 (-0.05; -0.19) 0.237
CCQ (symptoms) 1.86 (± 0.94) 1.83 (± 1.03) -0.03 (-0.17; -0.11) 0.686
CCQ (functional) 1.34 (± 1.11) 1.47 (± 1.16) 0.13 (-0.02; 0.28) 0.087
CCQ (mental state) 0.54 (± 0.83) 0.66 (± 0.86) 0.11 (-0.02; 0.24) 0.088
Health Status (VAS)† (scale 0-10) 6.99 (± 1.34) 6.97 (± 1.54) -0.03 (-0.22; 0.16) 0.758
Symptoms
Dyspnoea (MRC) (scale 0-5)* 1.61 (± 1.06) 1.30 (± 1.07) -0.31 (-0.47; -0.15) < 0.001
Dyspnoea (Borg) (scale 0-10)* 2.42 (± 1.62) 2.01 (± 1.28) -0.41(-0.65; -0.17) 0.001
Lung function (FEV1 % predicted)
† 76.93 (± 17.96) 73.59 (± 18.53) -3.34 (-4.94; -1.75) < 0.001
Patient experiences†
General practitioner (scale 0-10) 6,95 (± 1.69) 7,00 (± 1.70) 0.46 (-0.32; 0.41) 0.804
Practice nurse (scale 0-10) 5,60 (± 1.87) 7,15 (± 1.44) 1.55 (0.82; 2.28) < 0.001
* Negative change means improvement; † Positive change means improvement
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more comprehensive self-management component
within the programme, such as motivational interview-
ing instead of patient education, seems most promising
to this end [36].
Findings of this study must be interpreted in the light
of several limitations. First, the lack of a control group
means that it can not be assumed that positive effects
of this study were solely due to the programme [37].
However, we found no reason to assume that elements
such as the introduction of new medications on the
health care market or changes in the insurance system
occurred that could have caused improvements of com-
parable magnitude. The included general practices were
representative for other Dutch practices. Since rando-
misation is not feasible in such a setting a viable alter-
native design would be interrupted time series or a
delayed treatment design [38]. Yet, a theory-driven
approach, as used in this study, to understanding com-
plex social interventions and their effects is very valu-
able. Nevertheless we fully acknowledge that results
have to be interpreted with caution. Second, self-
reported instruments were used. Self-reporting of medi-
cation and exercise behaviour must be interpreted as an
estimate of particular behaviours. Still, the multi-item
scales used met standards for reliability, and support
for validity has been reported for several measures
[15,16,19,20]. Third, data on cost-effectiveness were not
gathered, due to separate registration systems within
general practices and the hospital. Considering that
ever tightening budgets cannot meet the continuously
increasing demand for healthcare, it is important to
assess the costs and cost effectiveness of disease-man-
agement programmes. And finally, not all proposed
model associations have been tested, because of the
absence of significant changes in some intermediate
outcomes. Previous research already showed associa-
tions between behaviour and quality of life in cross-sec-
tional data [39]. Future research should therefore focus
on testing associations between changes in patient and
professional behaviour (independent variables) and
changes in outcomes of care (dependent variables).
Conclusions
The application of a theoretical model improves the
design and evaluation of disease management pro-
grammes. It helps to understand the context and the
processes of the intervention, and to select the appro-
priate indicators for evaluation. Although results have
to be interpreted with caution due to the research
design, this study provides prudent evidence that the
implementation of disease management for patients
with COPD can positively influence outcomes of care.
Moreover, stronger effects may emerge in the long
run.Ta
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Additional file 1: Practice characteristics. An overview of practice
characteristics of the included general practices in this study as
compared to characteristics of other general practices in the Netherlands.
Additional file 2: Disease management interventions in the
‘Gelderse Vallei’ region. An overview of the content of the
interventions which were implemented as a part of the disease
management programmes
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